Literature DB >> 18846101

Hypoxia signalling through mTOR and the unfolded protein response in cancer.

Bradly G Wouters1, Marianne Koritzinsky.   

Abstract

Hypoxia occurs in the majority of tumours, promoting angiogenesis, metastasis and resistance to therapy. Responses to hypoxia are orchestrated in part through activation of the hypoxia-inducible factor family of transcription factors (HIFs). Recently, two additional O(2)-sensitive signalling pathways have also been implicated: signalling through the mammalian target of rapamycin (mTOR) kinase and signalling through activation of the unfolded protein response (UPR). Although they are activated independently, growing evidence suggests that HIF-, mTOR- and UPR-dependent responses to hypoxia act in an integrated way, influencing each other and common downstream pathways that affect gene expression, metabolism, cell survival, tumorigenesis and tumour growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18846101     DOI: 10.1038/nrc2501

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  367 in total

Review 1.  Tumor hypoxia and genetic alterations in sporadic cancers.

Authors:  Minoru Koi; Clement R Boland
Journal:  J Obstet Gynaecol Res       Date:  2011-01-27       Impact factor: 1.730

2.  The unfolded protein response regulates an angiogenic response by the kidney epithelium during ischemic stress.

Authors:  Nicolas Bouvier; Sophie Fougeray; Philippe Beaune; Eric Thervet; Nicolas Pallet
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

3.  O(2) regulates skeletal muscle progenitor differentiation through phosphatidylinositol 3-kinase/AKT signaling.

Authors:  Amar J Majmundar; Nicolas Skuli; Rickson C Mesquita; Meeri N Kim; Arjun G Yodh; Michelle Nguyen-McCarty; M Celeste Simon
Journal:  Mol Cell Biol       Date:  2011-10-17       Impact factor: 4.272

4.  Akt determines cell fate through inhibition of the PERK-eIF2α phosphorylation pathway.

Authors:  Zineb Mounir; Jothi Latha Krishnamoorthy; Shuo Wang; Barbara Papadopoulou; Shirley Campbell; William J Muller; Maria Hatzoglou; Antonis E Koromilas
Journal:  Sci Signal       Date:  2011-09-27       Impact factor: 8.192

5.  Hypoxia-Sensitive COMMD1 Integrates Signaling and Cellular Metabolism in Human Macrophages and Suppresses Osteoclastogenesis.

Authors:  Koichi Murata; Celestia Fang; Chikashi Terao; Eugenia G Giannopoulou; Ye Ji Lee; Min Joon Lee; Se-Hwan Mun; Seyeon Bae; Yu Qiao; Ruoxi Yuan; Moritoshi Furu; Hiromu Ito; Koichiro Ohmura; Shuichi Matsuda; Tsuneyo Mimori; Fumihiko Matsuda; Kyung-Hyun Park-Min; Lionel B Ivashkiv
Journal:  Immunity       Date:  2017-07-18       Impact factor: 31.745

Review 6.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

Review 7.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

8.  Neuroprotection Through Rapamycin-Induced Activation of Autophagy and PI3K/Akt1/mTOR/CREB Signaling Against Amyloid-β-Induced Oxidative Stress, Synaptic/Neurotransmission Dysfunction, and Neurodegeneration in Adult Rats.

Authors:  Abhishek Kumar Singh; Mahendra Pratap Kashyap; Vinay Kumar Tripathi; Sandeep Singh; Geetika Garg; Syed Ibrahim Rizvi
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  Aspirin may inhibit angiogenesis and induce autophagy by inhibiting mTOR signaling pathway in murine hepatocarcinoma and sarcoma models.

Authors:  Qianqian Zhao; Zhaopeng Wang; Zhaoxia Wang; Licun Wu; Weidong Zhang
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

10.  Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.

Authors:  Merryl R Lobo; Sarah C Green; Matthias C Schabel; G Yancey Gillespie; Randall L Woltjer; Martin M Pike
Journal:  Neuro Oncol       Date:  2013-10-03       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.